DrugPatentWatch Database Preview

Details for Patent: 10,449,176

« Back to Dashboard

Which drugs does patent 10,449,176 protect, and when does it expire?

Patent 10,449,176 protects HETLIOZ and is included in one NDA.

This patent has ninety-nine patent family members in twenty-one countries.

Summary for Patent: 10,449,176

Title:	Treatment of circadian rhythm disorders
Abstract:	Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Inventor(s):	Dressman; Marlene Michelle (Germantown, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD)
Assignee:	VANDA PHARMACEUTICALS INC. (Washington, DC)
Application Number:	15/822,162
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,449,176
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,449,176

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014		RX	Yes	Yes						TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON

International Family Members for US Patent 10,449,176

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013211878
Australia	2013211880
Australia	2013361459